SCHEMBL7054882

SCHEMBL7054882

CCCCc1nc(Cl)c(CC(N)=O)n1Cc1ccccc1

nearest known ligand 0.82

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
AGTR1 P30556 3/20 0.67
AGTR2 P50052 3/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11269513 0.90 AGTR1 (0.80) AGTR1AGTR2
Hydrochloric Acid SCHEMBL11096786 0.84 AGTR1 (0.62) AGTR1AGTR2
SCHEMBL11100306 0.84 AGTR1 (0.72) AGTR1AGTR2
SCHEMBL9590556 0.82 AGTR1 (0.79) AGTR1AGTR2
SCHEMBL251 0.80 AGTR1 (1.00) AGTR1AGTR2
SCHEMBL1569312 0.79 AGTR1 (0.67) AGTR1AGTR2
SCHEMBL312 0.78 AGTR1 (0.72) AGTR1AGTR2
SCHEMBL9700729 0.78 AGTR1 (0.54) AGTR1AGTR2
SCHEMBL11093753 0.78 AGTR1 (0.56) AGTR1AGTR2
SCHEMBL298 0.77 AGTR1 (0.66) AGTR1AGTR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4340598-A Hypotensive imidazole derivatives TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1982-07-20 US claimed
US-20030187044-A1 Medicament SMITHKLINE BEECHAM P.L.C. 2003-10-02 US disclosed
US-20030166700-A1 Administering a substituted imidazoles to a mammal for the treatment of athroma progression and regression SMITHKLINE BEECHAM P.L.C. 2003-09-04 US disclosed
US-20030096851-A1 Medicament SMITHKLINE BEECHAM P.L.C. 2003-05-22 US disclosed
EP-0724387-B1 ANGIOTENSION II RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CHRONIC ANTI-INFLAMMATORY DISEASES SMITHKLINE BEECHAM CORP (US) 2003-05-02 EP disclosed
US-20030069293-A1 Medicament SMITHKLINE BEECHAM PLC 2003-04-10 US disclosed
US-20030050285-A1 Substituted imidazoles; angiotensin II receptor antagonist for the treatment of hemorrhagic stroke SMITHKLINE BEECHAM P.L.C. 2003-03-13 US disclosed
US-20030004201-A1 Medicament SMITHKLINE BEECHAM P.L.C. 2003-01-02 US disclosed
US-20020160985-A1 Medicament SMITHKLINE BEECHAM PLC 2002-10-31 US disclosed
US-20020132840-A1 Treating angina in a mammal by administering an angiotensin II receptor antagonist. SMITHKLINE BEECHAM P.1.C. 2002-09-19 US disclosed
WO-1992010183-A1 USE OF ANGIOTENSIN II RECEPTOR ANTAGONISTS IN THE TREATMENT OF DIABETIC RETINOPATHY SMITHKLINE BEECHAM PLC (GB) 1992-06-25 WO disclosed
WO-1992010186-A1 USE OF ANGIOTENSN II RECEPTOR ANTAGONISTS FOR THE PREPARATION OF A MEDICAMENT FOR IMPROVING COGNITIVE FUNCTION SMITHKLINE BEECHAM PLC (GB) 1992-06-25 WO disclosed
WO-1992010185-A1 USE OF ANGIOTENSIN II RECEPTOR ANTAGONISTS IN THE PREVENTION OF RESTINOSIS SMITHKLINE BEECHAM PLC (GB) 1992-06-25 WO disclosed
WO-1992002510-A1 SUBSTITUTED [1H-IMIDAZOL-5-YL]ALKANOIC ACIDS SMITHKLINE BEECHAM CORPORATION (US) 1992-02-20 WO disclosed
WO-1992000068-A1 SUBSTITUTED HISTIDINES SMITHKLINE BEECHAM CORPORATION (US) 1992-01-09 WO disclosed
WO-1991016313-A1 SUBSTITUTED BENZIMIDAZOLES SMITHKLINE BEECHAM CORPORATION (US) 1991-10-31 WO disclosed
US-5036048-A Angiotensin II receptor blockers as antiglaucoma agents SCHERING CORPORATION (US) 1991-07-30 US disclosed
EP-0437103-A2 Substituted 5-(alkyl)carboxamide imidazoles SMITHKLINE BEECHAM CORPORATION (US) 1991-07-17 EP disclosed
EP-0427463-A1 Substituted N-(imidazolyl)alkyl alanine derivatives SMITHKLINE BEECHAM CORPORATION (US) 1991-05-15 EP disclosed
US-4340598-A Hypotensive imidazole derivatives TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1982-07-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020160985-A1 Medicament AGTR2, AGTR1, ACE AGTR1 2/4885AGTR2 1/4885
US-20020132840-A1 Treating angina in a mammal by administering an angiotensin II receptor antagonist. AGTR2, AGTR1, AGT AGTR1 2/4885AGTR2 1/4885
US-20030187044-A1 Medicament AGTR2, AGTR1, ACE AGTR1 2/4885AGTR2 1/4885
US-20030004201-A1 Medicament AGTR2, AGTR1, ACE AGTR1 2/4885AGTR2 1/4885
US-20030166700-A1 Administering a substituted imidazoles to a mammal for the treatment of athroma progression and regression AGTR1, AGTR2, AGT AGTR1 1/4885AGTR2 2/4885
US-20030096851-A1 Medicament AGTR2, AGTR1, ACE AGTR1 2/4885AGTR2 1/4885
US-20030050285-A1 Substituted imidazoles; angiotensin II receptor antagonist for the treatment of hemorrhagic stroke AGTR2, AGTR1, ACE AGTR1 2/4885AGTR2 1/4885
US-20030069293-A1 Medicament AGTR2, AGTR1, ACE AGTR1 2/4885AGTR2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.